- Home
- SGLY vs AYTU Comparison
SGLY vs AYTU Comparison
Compare SGLY & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- AYTU
- Stock Information
- Founded
- SGLY 2001
- AYTU N/A
- Country
- SGLY United States
- AYTU United States
- Employees
- SGLY N/A
- AYTU N/A
- Industry
- SGLY
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- AYTU Health Care
- Exchange
- SGLY Nasdaq
- AYTU Nasdaq
- Market Cap
- SGLY 5.8M
- AYTU 9.8M
- IPO Year
- SGLY 2008
- AYTU N/A
- Fundamental
- Price
- SGLY $1.55
- AYTU $1.38
- Analyst Decision
- SGLY
- AYTU
- Analyst Count
- SGLY 0
- AYTU 0
- Target Price
- SGLY N/A
- AYTU N/A
- AVG Volume (30 Days)
- SGLY 14.2K
- AYTU 37.2K
- Earning Date
- SGLY 11-14-2024
- AYTU 02-12-2025
- Dividend Yield
- SGLY N/A
- AYTU N/A
- EPS Growth
- SGLY N/A
- AYTU N/A
- EPS
- SGLY N/A
- AYTU N/A
- Revenue
- SGLY $2,742,157.00
- AYTU $79,759,000.00
- Revenue This Year
- SGLY N/A
- AYTU N/A
- Revenue Next Year
- SGLY N/A
- AYTU N/A
- P/E Ratio
- SGLY N/A
- AYTU N/A
- Revenue Growth
- SGLY N/A
- AYTU N/A
- 52 Week Low
- SGLY $1.27
- AYTU $1.30
- 52 Week High
- SGLY $7.65
- AYTU $3.45
- Technical
- Relative Strength Index (RSI)
- SGLY 43.10
- AYTU 33.90
- Support Level
- SGLY $1.58
- AYTU $1.30
- Resistance Level
- SGLY $1.71
- AYTU $1.47
- Average True Range (ATR)
- SGLY 0.09
- AYTU 0.12
- MACD
- SGLY -0.00
- AYTU -0.01
- Stochastic Oscillator
- SGLY 35.71
- AYTU 17.78
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.